(TER bin a feen)
- Terbinafine HCl
- Terbinafine Hydrochloride
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Cream, External, as hydrochloride:
LamISIL AT: 1% (12 g, 24 g, 30 g, 36 g, 42 g) [contains benzyl alcohol, cetyl alcohol]
LamISIL AT Jock Itch: 1% (12 g) [contains benzyl alcohol, cetyl alcohol]
Generic: 1% (12 g [DSC], 15 g, 24 g [DSC], 30 g)
LamISIL Advanced: 1% (12 g) [contains alcohol, usp]
Solution, External, as hydrochloride:
LamISIL AT Spray: 1% (30 mL [DSC], 125 mL) [contains alcohol, usp, propylene glycol]
LamISIL Spray: 1% (30 mL [DSC]) [contains alcohol, usp]
Brand Names: U.S.
- LamISIL Advanced [OTC]
- LamISIL AT Jock Itch [OTC]
- LamISIL AT Spray [OTC]
- LamISIL AT [OTC]
- LamISIL Spray [DSC]
- Antifungal Agent, Topical
Synthetic allylamine derivative which inhibits squalene epoxidase, a key enzyme in sterol biosynthesis in fungi. This results in a deficiency in ergosterol within the fungal cell wall and results in fungal cell death.
Distributed to sebum and skin predominantly
14 to 35 hours
Use: Labeled Indications
Antifungal for the treatment of tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm) [OTC/Canadian prescription formulations]; cutaneous candidiasis and tinea versicolor [Canadian prescription formulations]
Hypersensitivity to terbinafine or any component of the formulation
Tinea pedis: Topical:
Cream: Apply between the toes to affected area once or twice daily for at least 1 week [OTC/Canadian prescription formulations]; apply on the bottom or sides of feet twice daily for 2 weeks [OTC formulations]
Gel: Apply to affected area once daily for at least 1 week [OTC formulations]
Solution: Apply to affected area once daily for at least 1 week [OTC/Canadian prescription formulations]
Tinea corporis, Tinea cruris: Topical:
Cream: Apply to affected area once daily for 1 week [OTC/Canadian prescription formulations]
Gel: Apply to affected area once daily for 1 week [OTC formulations]
Solution: Apply to affected area once daily for 1 week [OTC/Canadian prescription formulations]
Cutaneous candidiasis: Apply to affected area once or twice daily for 1-2 weeks [Canadian prescription formulation]
Tinea versicolor: Topical:
Cream: Apply to affected area once or twice daily for 1-2 weeks [Canadian prescription formulation]
Solution: Apply to affected area twice daily for 1 week [Canadian prescription formulation]
Refer to adult dosing.
Tinea pedis: Children ≥12 years and Adolescents: Topical:
Cream: Apply between the toes to affected area twice daily for at least 1 week [OTC formulations]; apply on the bottom or sides of feet twice daily for 2 weeks [OTC formulations]
Gel, Solution: Refer to adult dosing .
Tinea corporis, Tinea cruris: Children ≥12 years and Adolescents: Refer to adult dosing.
Wash affected area with soap and water prior to use and dry completely; wash hands after use.
Solution: Hold 4-6 inches from skin during use.
Cream: Store at 20°C to 25°C (68°F to 77°F).
Gel: Store at ≤30°C (≤86°F).
Solution: Store at 8°C to 25°C (46°F to 77°F).
There are no known significant interactions.
1% to 10%:
Dermatologic: Burning sensation of skin, contact dermatitis, exfoliation of skin, pruritus, skin irritation, skin rash, stinging of the skin, xeroderma
Local: Local irritation
Concerns related to adverse events:
• Local irritation: If irritation/sensitivity develops, discontinue therapy and institute appropriate alternative therapy.
Dosage form specific issues:
• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.
• Appropriate use: For topical use only. Not intended for ophthalmologic, oral, or vaginal administration. Do not use on nails or scalp.
Adverse events were not observed in animal reproduction studies with systemic terbinafine. Systemic absorption is limited following topical application.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience burning, stinging, or itching. Have patient report immediately to prescriber severe skin irritation (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
More about terbinafine topical
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Pricing & Coupons
- 9 Reviews – Add your own review/rating